Hepatitis Monthly

Published by: Kowsar

Adherence to Chronic Hepatitis C Treatment Regimen: First Report From a Referral Center in Iran

Saeedeh Ravi 1 , 2 , Mohsen Nasiri Toosi 3 , Iman Karimzadeh 1 , Mehdi Ahadi-Barzoki 4 and Hossein Khalili 1 , *
Authors Information
1 Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IR Iran
2 Department of Clinical Pharmacy, Pharmaceutical Sciences Branch, Islamic Azad University,, Tehran, IR Iran
3 Department of Gastroenterology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, IR Iran
4 Department of Clinical Pharmacy, Faculty of Pharmacy, Zanjan University of Medical Sciences, Zanjan, IR Iran
Article information
  • Hepatitis Monthly: June 2013, 13 (6); e11038
  • Published Online: June 23, 2013
  • Article Type: Research Article
  • Received: March 3, 2013
  • Revised: April 8, 2013
  • Accepted: May 25, 2013
  • DOI: 10.5812/hepatmon.11038

To Cite: Ravi S, Nasiri Toosi M, Karimzadeh I, Ahadi-Barzoki M, Khalili H. et al. Adherence to Chronic Hepatitis C Treatment Regimen: First Report From a Referral Center in Iran, Hepat Mon. 2013 ;13(6):e11038. doi: 10.5812/hepatmon.11038.

Copyright: Copyright © 2013, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Butt AA. Hepatitis C virus infection: the new global epidemic. Expert Rev Anti Infect Ther. 2005; 3(2): 241-9[DOI][PubMed]
  • 2. Craxi A, Laffi G, Zignego AL. Hepatitis C virus (HCV) infection: a systemic disease. Mol Aspects Med. 2008; 29(1-2): 85-95[DOI][PubMed]
  • 3. Fallahian F, Najafi A. Epidemiology of hepatitis C in the Middle East. Saudi J Kidney Dis Transpl. 2011; 22(1): 1-9[PubMed]
  • 4. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009; 29 Suppl 1: 74-81[DOI][PubMed]
  • 5. Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR, et al. Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int J Infect Dis. 2010; 14 Suppl 3-6[DOI][PubMed]
  • 6. Craxì A, Pawlotsky J-M, Wedemeyer H. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol. 2011; 55(2): 245-64
  • 7. Weiss JJ, Brau N, Stivala A, Swan T, Fishbein D. Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research. Aliment Pharmacol Ther. 2009; 30(1): 14-27[DOI][PubMed]
  • 8. Cacoub P, Ouzan D, Melin P, Lang J-P, Rotily M, Fontanges T, et al. Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: a prospective, real-life, observational study. World journal of gastroenterology: WJG. 2008; 14(40): 6195
  • 9. Hughes CA, Shafran SD. Chronic hepatitis C virus management: 2000-2005 update. Ann Pharmacother. 2006; 40(1): 74-82[DOI][PubMed]
  • 10. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002; 123(4): 1061-9[PubMed]
  • 11. Seeff LB, Hoofnagle JH. National Institutes of Health consensus development conference: management of hepatitis C: 2002. Hepatology. 2002; 36(5B)
  • 12. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49(4): 1335-74[DOI][PubMed]
  • 13. Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002; 35(6): 1522-7[DOI][PubMed]
  • 14. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998; 339(21): 1485-92[DOI][PubMed]
  • 15. Pianko S, McHutchison JG. Treatment of hepatitis C with interferon and ribavirin. Journal of gastroenterology and hepatology. 2000; 15(6): 581-6
  • 16. Numata M, Kagawa T, Kojima S-i, Hirose S, Nagata N, Shiraishi K, et al. Differential impact of adherence to pegylated interferon and ribavirin in the treatment of genotype 1 high viral titer chronic hepatitis C. Hepatitis research and treatment. 2010; 2010
  • 17. Sola R, Galeras JA, Montoliu S, Tural C, Force L, Torra S, et al. Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment. AIDS Res Hum Retroviruses. 2006; 22(5): 393-400[DOI][PubMed]
  • 18. Weiss JJ, Bhatti L, Dieterich DT, Edlin BR, Fishbein DA, Goetz MB, et al. Hepatitis C patients’ self‐reported adherence to treatment with pegylated interferon and ribavirin. Aliment Pharmacol Ther. 2008; 28(3): 289-93
  • 19. Paterson DL, Potoski B, Capitano B. Measurement of adherence to antiretroviral medications. J Acquir Immune Defic Syndr. 2002; 31 Suppl 3-6[PubMed]
  • 20. Smith SR, Wahed AS, Kelley SS, Conjeevaram HS, Robuck PR, Fried MW. Assessing the validity of self-reported medication adherence in hepatitis C treatment. Ann Pharmacother. 2007; 41(7): 1116-23[DOI][PubMed]
  • 21. Wagner GJ. Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries. AIDS Patient Care STDS. 2002; 16(12): 599-608[DOI][PubMed]
  • 22. Nieuwkerk PT, Oort FJ. Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: a meta-analysis. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2005; 38(4): 445-8
  • 23. Re III VL, Teal V, Localio AR, Amorosa VK, Kaplan DE, Gross R. Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study. Annals of Internal Medicine. 2011; 155(6): 353
  • 24. Lima VD, Harrigan R, Bangsberg DR, Hogg RS, Gross R, Yip B, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr. 2009; 50(5): 529-36[DOI][PubMed]
  • 25. Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005; 165(10): 1147-52[DOI][PubMed]
  • 26. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA: the journal of the American Medical Association. 2002; 288(4): 455-61
  • 27. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006; 55(9): 1350-9[DOI][PubMed]
  • 28. Arase Y, Suzuki F, Sezaki H, Kawamura Y, Suzuki Y, Kobayashi M, et al. Efficacy in patients with dose reduction in combination therapy of peginterferon and ribavirin for chronic hepatitis C. Intervirology. 2008; 51(1): 1-6[DOI][PubMed]
  • 29. Hiramatsu N, Oze T, Yakushijin T, Inoue Y, Igura T, Mochizuki K, et al. Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin. J Viral Hepat. 2009; 16(8): 586-94[DOI][PubMed]
  • 30. Reddy KR, Shiffman ML, Morgan TR, Zeuzem S, Hadziyannis S, Hamzeh FM, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol. 2007; 5(1): 124-9[DOI][PubMed]
  • 31. Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology. 2007; 132(1): 103-12[DOI][PubMed]
  • 32. Sylvestre DL, Clements BJ. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol. 2007; 19(9): 741-7[DOI][PubMed]
  • 33. Khalili H, Rohani R, Seyedalinaghi S, Hajiabdolbaghi M, Dashti-Khavidaki S, Hajhosssein Talasaz A. Adherence to antiretroviral therapy among Iranian HIV/AIDS patients. Current Clinical Pharmacology. 2012; 7(2): 111-5
  • 34. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004; 292(23): 2839-48[DOI][PubMed]
  • 35. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004; 351(5): 451-9[DOI][PubMed]
  • 36. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004; 351(5): 438-50[DOI][PubMed]
  • 37. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347(13): 975-82[DOI][PubMed]
  • 38. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. The Lancet. 2001; 358(9286): 958-65
  • 39. Alavi Moghaddam M, Zali MR, Aalaei Andabili SH, Derakhshan F, Miri SM, Alavian SM. High Rate of Virological Response to Peginterferon alpha-2a-Ribavirin Among Non-Cirrhotic Iranian Hemophilia Patients With Chronic Hepatitis C. Iran Red Crescent Med J. 2012; 14(8): 466-9[PubMed]
  • 40. Alavian SM, Tabatabaei SV, Keshvari M, Behnava B, Miri SM, Elizee PK, et al. Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases. Liver Int. 2010; 30(8): 1173-80[DOI][PubMed]
  • 41. Jabbari H, Bayatian A, Sharifi AH, Zaer-Rezaee H, Fakharzadeh E, Asadi R, et al. Safety and efficacy of locally manufactured pegylated interferon in hepatitis C patients. Arch Iran Med. 2010; 13(4): 306-12[PubMed]
  • 42. Namazee N, Sali S, Asadi S, Shafiei M, Behnava B, Alavian SM. Real response to therapy in chronic hepatitis C virus patients: a study from iran. Hepat Mon. 2012; 12(9)[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader